Patents Assigned to VAXIMM GMBH
  • MSLN targeting DNA vaccine for cancer immunotherapy
    Patent number: 10441645
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 15, 2019
    Assignee: VAXIMM GMBH
    Inventors: Marco Springer, Heinz Lubenau
  • NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317634
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Vaximm GMBH Mafinex-Technologiezentrum
    Inventors: Marco SPRINGER, Heinz LUBENAU